The Department of Health and Human Services via the National Institute of Allergy & Infectious Diseases (NIAID) has awarded VenatoRx Pharmaceuticals Inc. $21,232,922 for the “Development of Therapeutic Medical Countermeasures for Biodefense and Emerging Infectious Diseases”.
VenatoRx is a Pennsylvania-based company focused on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. with new generations of existing antibacterial classes and new approaches to known antibacterial targets.
The award was announced under Solicitation Number: BAA-NIAID-DMID-NIHAI2012149.
